TOKYO, Dec 18 (Reuters) - Japan’s Shionogi & Co said on Tuesday that it has applied to health regulators in the United States, Canada and Europe for approval of its HIV drug Dolutegravir. Shionogi developed Dolutegravir with a Viiv Healthcare, an AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug.
The United States will not approve of the HIV drug
( z1 approve :polarity - :ARG0 ( z2 country :name ( z3 name :op "United" :op "States" ) ) :ARG1 ( z4 drug :mod ( z5 disease :name ( z6 name :op "HIV" ) ) ) )